Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    (R)-(-)-Menthol

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Expands Market Access, Authorizes New ENDS Products
    FDA Expands Market Access, Authorizes New ENDS Products

    05 May 2026

    // FDA

    https://www.fda.gov/news-events/press-announcements/fda-expands-market-access-authorizes-new-ends-products

    FDA
    05 May 2026
    Share Share
    FDgard® shows Excellent Safety And Tolerability Profile for Functional Dyspepsia
    FDgard® shows Excellent Safety And Tolerability Profile for Functional Dyspepsia

    28 Oct 2019

    // PR NEWS WIRE

    https://www.prnewswire.com/news-releases/in-the-longest-running-post-marketing-surveillance-study-of-its-type-data-at-24-months-on-fdgard-presented-at-the-american-college-of-gastroenterology-acg-annual-meeting-confirms-excellent-safety-and-tolerability-profile-of--300946011.html

    PR NEWS WIRE
    28 Oct 2019
    Share Share
    Enforcement Report - Week of May 30, 2018
    Enforcement Report - Week of May 30, 2018

    29 May 2018

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-may-30-2018-1527659653.pdf

    FDA
    29 May 2018
    Share Share
    Enforcement Report - Week of March 1, 2017
    Enforcement Report - Week of March 1, 2017

    01 Mar 2017

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-march-1-2017-1488363970.pdf

    FDA
    01 Mar 2017
    Share Share
    200 out of 500 combinations examined have been found irrational: Govt sources
    200 out of 500 combinations examined have been found irrational: Govt sources

    17 Nov 2016

    // Veena Mani BUSINESS STANDARD

    http://www.business-standard.com/article/companies/200-out-of-500-combinations-examined-have-been-found-irrational-govt-sources-116111601364_1.html

    Veena Mani BUSINESS STANDARD
    17 Nov 2016
    Share Share
    Formulation and Taste Masking of Ranitidine Orally Disintegrating Tablet
    Formulation and Taste Masking of Ranitidine Orally Disintegrating Tablet

    17 Nov 2016

    // PHARMA EXCIPIENTS

    https://www.pharmacompass.com/pdf/news/formulation-and-taste-masking-of-ranitidine-orally-disintegrating-tablet-1479468707.pdf

    PHARMA EXCIPIENTS
    17 Nov 2016
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.